ThinkEquity Upgrades ViroPharma (VPHM) to Buy
More News related to VPHM
- ViroPharma (VPHM) Updates on Cinryze FY09 Sales
- ViroPharma (VPHM) Acquires Rights for Cinryze Development and Commercialization
- ViroPharma Provides 2010 Cinryze(TM) (C1 Esterase Inhibitor [Human]) Outlook
- ViroPharma Expands Global Licensing, Commercialization and Development Rights for Cinryze(TM) (C1 esterase inhibitor [human])
- ViroPharma to Participate in the 28th Annual J.P. Morgan Healthcare Conference
More News related to Upgrades
- Raymond James Upgrades Cimarex Energy (XEC) to Outperform
- Barclays Upgrades Vodafone (VOD) to Overweight
- Credit Suisse Upgrades CarMax (KMX) to Neutral
- Argus Upgrades Universal Technical Institute (UTI) to Buy
- Argus Upgrades UPS (UPS) to Buy
ThinkEquity upgrades ViroPharma (Nasdaq: VPHM) from Source of Funds to Buy.
To see more analyst ratings on VPHM Click Here.
ViroPharma Incorporated, a biopharmaceutical company, engages in the development and commercialization of products that address serious diseases with a focus on products used by physician specialists or in hospital settings in the United States and internationally.
Related Categories
UpgradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
